Neuroblastoma: Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma

Science Translational Medicine

Volumn 3, Issue 108, 2011, Pages

  Bresler, Scott C ^a   Wood, Andrew C ^a,b   Haglund, Elizabeth A ^a,b   Courtright, Joshua ^a,b   Belcastro, Lili T ^a,b   Plegaria, Jefferson S ^a,b   Cole, Kristina ^a,b   Toporovskaya, Yana ^a,b   Zhao, Huaqing ^a,b   Carpenter, Erica L ^a,b   Christensen, James G ^c   Maris, John M ^a,b,d   Lemmon, Mark A ^a   Mossé, Yaël P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ANAPLASTIC LYMPHOMA KINASE; MUTANT PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANAPLASTIC LYMPHOMA KINASE GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; MUTATOR GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN GENOME; KINETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; KINETICS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 81055126433     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002950     Document Type: Article

References (39)

1. G. J. D'Angio, A. E. Evans, C. E. Koop, Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1, 1046-1049 (1971).
2. W. L. Hobbie, T. Moshang, C. A. Carlson, E. Goldmuntz, N. Sacks, S. B. Goldfarb, S. A. Grupp, J. P. Ginsberg, Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr. Blood Cancer 51, 679-683 (2008).
3. T. Iwahara, J. Fujimoto, D. Wen, R. Cupples, N. Bucay, T. Arakawa, S. Mori, B. Ratzkin, T. Yamamoto, Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439-449 (1997).
4. S. W. Morris, M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro, D. L. Saltman, A. T. Look, Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284 (1994).
5. M. Soda, Y. L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano, Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448, 561-566 (2007).
6. R. H. Palmer, E. Vernersson, C. Grabbe, B. Hallberg, Anaplastic lymphoma kinase: Signalling in development and disease. Biochem. J. 420, 345-361 (2009).
7. Y. P. Mossé, M. Laudenslager, L. Longo, K. A. Cole, A. Wood, E. F. Attiyeh, M. J. Laquaglia, R. Sennett, J. E. Lynch, P. Perri, G. Laureys, F. Speleman, C. Kim, C. Hou, H. Hakonarson, A. Torkamani, N. J. Schork, G. M. Brodeur, G. P. Tonini, E. Rappaport, M. Devoto, J. M. Maris, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
8. H. Carén, F. Abel, P. Kogner, T. Martinsson, High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416, 153-159 (2008).
9. Y. Chen, J. Takita, Y. L. Choi, M. Kato, M. Ohira, M. Sanada, L. Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa, Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
10. R. E. George, T. Sanda, M. Hanna, S. Fröhling, W. Luther II, J. Zhang, Y. Ahn, W. Zhou, W. B. London, P.McGrady, L. Xue, S. Zozulya, V. E. Gregor, T. R. Webb, N. S. Gray, D. G. Gilliland, L. Diller, H. Greulich, S. W. Morris, M. Meyerson, A. T. Look, Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
11. I. Janoueix-Lerosey, D. Lequin, L. Brugières, A. Ribeiro, L. de Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron, D. Valteau-Couanet, T. Frebourg, J. Michon, S. Lyonnet, J. Amiel, O. Delattre, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
12. S. De Brouwer, K. De Preter, C. Kumps, P. Zabrocki, M. Porcu, E. M. Westerhout, A. Lakeman, J. Vandesompele, J. Hoebeeck, T. Van Maerken, A. De Paepe, G. Laureys, J. H. Schulte, A. Schramm, C. Van Den Broecke, J. Vermeulen, N. Van Roy, K. Beiske, M. Renard, R. Noguera, O. Delattre, I. Janoueix-Lerosey, P. Kogner, T. Martinsson, A. Nakagawara, M. Ohira, H. Caron, A. Eggert, J. Cools, R. Versteeg, F. Speleman, Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353-4362 (2010).
13. A. K. Murugan, M. Xing, Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 71, 4403-4411 (2011).
14. J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, G. Los, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322 (2007).
15. E. L. Kwak, Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
16. Y. L. Choi, M. Soda, Y. Yamashita, T. Ueno, J. Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano; ALK Lung Cancer Study Group, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010).
17. T. Sasaki, K. Okuda, W. Zheng, J. Butrynski, M. Capelletti, L. Wang, N. S. Gray, K. Wilner, J. G. Christensen, G. Demetri, G. I. Shapiro, S. J. Rodig, M. J. Eck, P. A. Jänne, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038-10043 (2010).
18. R. Katayama, T. M. Khan, C. Benes, E. Lifshits, H. Ebi, V. M. Rivera, W. C. Shakespeare, A. J. Iafrate, J. A. Engelman, A. T. Shaw, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. U.S.A. 108, 7535-7540 (2011).
19. P. Mazot, A. Cazes, M. C. Boutterin, A. Figueiredo, V. Raynal, V. Combaret, B. Hallberg, R. H. Palmer, O. Delattre, I. Janoueix-Lerosey, M. Vigny, The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 30, 2017-2025 (2011).
20. T. Martinsson, T. Eriksson, J. Abrahamsson, H. Caren, M. Hansson, P. Kogner, S. Kamaraj, C. Schönherr, J. Weinmar, K. Ruuth, R. H. Palmer, B. Hallberg, Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 71, 98-105 (2011).
21. C. Moog-Lutz, J. Degoutin, J. Y. Gouzi, Y. Frobert, N. Brunet-de Carvalho, J. Bureau, C. Créminon, M. Vigny, Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039-26048 (2005).
22. A. L. Shrout, D. J. Montefusco, R. M. Weis, Template-directed assembly of receptor signaling complexes. Biochemistry 42, 13379-13385 (2003).
23. X. Zhang, J. Gureasko, K. Shen, P. A. Cole, J. Kuriyan, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006).
24. R. T. Bossi, M. B. Saccardo, E. Ardini, M. Menichincheri, L. Rusconi, P. Magnaghi, P. Orsini, N. Avanzi, A. L. Borgia, M. Nesi, T. Bandiera, G. Fogliatto, J. A. Bertrand, Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49, 6813-6825 (2010).
25. A. Donella-Deana, O. Marin, L. Cesaro, R. H. Gunby, A. Ferrarese, A. M. Coluccia, C. J. Tartari, L. Mologni, L. Scapozza, C. Gambacorti-Passerini, L. A. Pinna, Unique substrate specificity of anaplastic lymphoma kinase (ALK): Development of phosphoacceptor peptides for the assay of ALK activity. Biochemistry 44, 8533-8542 (2005).
26. C. C. Lee, Y. Jia, N. Li, X. Sun, K. Ng, E. Ambing, M. Y. Gao, S. Hua, C. Chen, S. Kim, P. Y. Michellys, S. A. Lesley, J. L. Harris, G. Spraggon, Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J. 430, 425-437 (2010).
27. M. H. Cobb, B. C. Sang, R. Gonzalez, E. Goldsmith, L. Ellis, Autophosphorylation activates the soluble cytoplasmic domain of the insulin receptor in an intermolecular reaction. J. Biol. Chem. 264, 18701-18706 (1989).
28. S. Favelyukis, J. H. Till, S. R. Hubbard, W. T. Miller, Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 8, 1058-1063 (2001).
29. C. M. Furdui, E. D. Lew, J. Schlessinger, K. S. Anderson, Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 21, 711-717 (2006).
30. M. R. Grace, C. T. Walsh, P. A. Cole, Divalent ion effects and insights into the catalytic mechanism of protein tyrosine kinase Csk. Biochemistry 36, 1874-1881 (1997).
31. 2+-binding properties of a recombinant protein-tyrosine kinase derived from the human insulin receptor. Proc. Natl. Acad. Sci. U.S.A. 87, 2805-2809 (1990).
32. J. H. Till, M. Becerra, A. Watty, Y. Lu, Y. Ma, T. A. Neubert, S. J. Burden, S. R. Hubbard, Crystal structure of the MuSK tyrosine kinase: Insights into receptor autoregulation. Structure 10, 1187-1196 (2002).
33. M. J. Eck, C. H. Yun, Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim. Biophys. Acta 1804, 559-566 (2010).
34. P. Sabbatini, S. Korenchuk, J. L. Rowand, A. Groy, Q. Liu, D. Leperi, C. Atkins, M. Dumble, J. Yang, K. Anderson, R. G. Kruger, R. R. Gontarek, K. R. Maksimchuk, S. Suravajjala, R. R. Lapierre, J. B. Shotwell, J. W. Wilson, S. D. Chamberlain, S. K. Rabindran, R. Kumar, GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 8, 2811-2820 (2009).
35. S. V. Sharma, D. W. Bell, J. Settleman, D. A. Haber, Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
36. K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, M. X. Sliwkowski, Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163-8171 (2006).
37. C. H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K. K. Wong, M. Meyerson, M. J. Eck, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075 (2008).
38. W. Zhou, D. Ercan, L. Chen, C. H. Yun, D. Li, M. Capelletti, A. B. Cortot, L. Chirieac, R. E. Iacob, R. Padera, J. R. Engen, K. K. Wong, M. J. Eck, N. S. Gray, P. A. Jänne, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074 (2009).
39. Acknowledgments: We thank members of the Lemmon, Mossé, and Maris laboratories for valuable discussions, and Pfizer for their gift of crizotinib. Funding: This work was funded in part by the U.S. Army Peer-Reviewed Medical Research Program (W81XWH-10-1-0212/3 to M.A.L. and Y.P.M.), NIH grant R01-CA140198 (Y.P.M.), the Carly Hillman Fund (Y.P.M.), the Alex's Lemonade Stand Foundation (J.M.M.), and the Abramson Family Cancer Research Institute (J.M.M.). S.C.B. was supported by an NIH Training Grant in Structural Biology (T32-GM008275). A.C.W. was supported by a fellowship from the St. Baldrick's Foundation. Author contributions: S.C.B. designed and performed in vitro studies of ALK-TKD, analyzed and interpreted the data, and drafted the manuscript. A.C.W. designed and performed cellular and in vivo experiments, analyzed and interpreted the data, and drafted the manuscript. E.A.H., J.C., L.T.B., J.S.P., K.C., Y.T., and H.Z. made important contributions to cellular and in vivo experiments and/or data analysis. E.L.C., J.G.C., J.M.M., Y.P.M., and M.A.L. guided study design, implementation, and interpretation; provided conceptual direction; and wrote the manuscript with S.C.B. and A.C.W. Competing interests: J.G.C. is an employee of Pfizer, the developer of crizotinib. J.M.M. and Y.P.M. are authors on a patent related to the discovery of ALK mutations filed by the Children's Hospital of Philadelphia (WO/2009/103061 or PCT/US2009/034288: Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma). The other authors declare that they have no competing interests.